Get started
Author

Subramanian Loganathan

Observed names: Loganathan Subramanian, Loganathan, Subramanian, S. Loganathan
Institution: Biocon (India)
ORCID: 0000-0001-7186-0049
Observed ORCID: 0000-0001-7186-0049
OpenAlex ID: A5041082309
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial
2016 · Hope S. Rugo, Abhijit Barve, et al. · JAMA · 147
PDF
Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications
2020 · Subramanian Loganathan, Sandeep N. Athalye, et al. · Expert Opinion on Biological Therapy · 39
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
2021 · Suresh Kumar, Rosemarie De Souza, et al. · Expert Opinion on Biological Therapy · 37
Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial
2024 · Susan B. Bressler, Abhijit Barve, et al. · JAMA Ophthalmology · 23
PDF
Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study
2022 · Harold E Lebovitz, Alexander Fleming, et al. · Expert Opinion on Pharmacotherapy · 21
PDF
Ultrasound assisted polymerization of N-vinyl imidazole under phase-transfer catalysis condition – A kinetic study
2012 · Subramanian Loganathan, Venugopal Rajendran · Ultrasonics Sonochemistry · 16
Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus
2023 · Shashank Joshi, Vathsala Jayanth, et al. · Drugs · 15
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
2021 · Hope S. Rugo, Eduardo J. Pennella, et al. · Breast Cancer Research and Treatment · 15
PDF
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
2021 · Mark A. Socinski, Cornelius F. Waller, et al. · Therapeutic Advances in Medical Oncology · 10
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US ‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE ‐1 ( Recombinant Human INsulin Equivalence‐1 ) study
2022 · Leona Plum‐Mörschel, Gursharan Singh, et al. · Diabetes Obesity and Metabolism · 8
Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.
2019 · Cornelius F. Waller, Aleksei Manikhas, et al. · Journal of Clinical Oncology · 8
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study
2025 · Jacek C Szepietowski, Adam Reich, et al. · Expert Opinion on Biological Therapy · 7
Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial.
2018 · Aleksei Manikhas, Eduardo J. Pennella, et al. · Journal of Clinical Oncology · 7
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
2021 · Hope S. Rugo, Eduardo J. Pennella, et al. · The Breast · 6
PDF
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial
2025 · Jacek C. Szepietowski, Adam Reich, et al. · Expert Opinion on Biological Therapy · 5
PDF
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability
2025 · Sarika Deodhar, Subramanian Loganathan, et al. · Advances in Therapy · 5
PDF
Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the Study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1)
2025 · Jonathan Ackroyd, Sarika S Deodhar, et al. · Expert Opinion on Investigational Drugs · 5
An open‐label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability
2025 · Esther Latres, Leona Plum‐Moerschel, et al. · Diabetes Obesity and Metabolism · 3
PDF
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer
2023 · Joel S. Owen, Russell J. Rackley, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 3
Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis
2026 · Richard Eastell, Eric Orwoll, et al. · JBMR Plus · 2
RE covery and SUR vival of patients with moderate to severe acute RE spiratory distress syndrome (ARDS) due to C OVID-19: a multicenter, single-arm, Phase IV itolizumab T rial: RESURRECT
2023 · Raveendra KR, Chirag Rathod, et al. · Expert Opinion on Biological Therapy · 2
PDF
1391P Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC)
2020 · M.A. Socinski, C. Waller, et al. · Annals of Oncology · 2
A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the pharmacokinetics, safety, and tolerability of PERT-IJS following a single dose of 420 mg intravenous infusion compared to the EU- and US-marketed drug product (pertuzumab; PERT) in healthy male volunteers.
2025 · Subramanian Loganathan, Jelle Klein, et al. · Journal of Clinical Oncology · 1
PDF
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US ‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE ‐2 (Recombinant Human INsulin Equivalence‐2) study
2023 · Grit Andersen, Gursharan Singh, et al. · Diabetes Obesity and Metabolism · 1
PDF
Comparative pharmacokinetics of a proposed biosimilar bevacizumab Bmab-100 and reference product bevacizumab in a multicentre double blind randomized clinical trial in metastatic colorectal carcinoma (mCRC) patients
2017 · S. Beniwal, M. Kothekar, et al. · Annals of Oncology · 1
Works count: 42
Citation count: 387
H-index: 9
I10-index: 8
Year
Topic
Type